Palbociclib — Drug Intelligence | 39 EU Trials

Filter these 39 trials by condition, phase, country and more.

Open in Search →

39 Registered trials

12 Recruiting

26 Completed trials

28 Sponsors

21 Countries

Phase III

Phase II

Phase I/II

Phase III: 19 Phase II: 12 Phase I/II: 4 Phase III/IV: 1 Phase IV: 1 Phase I (FiH): 2

Oversight events:

1 serious breach 14 temporary halts 1 corrective measure across 3 trials

View oversight register →

Indications tested

Hormone receptor positive HER2 negative breast cancer 2 Breast cancer 2 Hormone receptor positive breast cancer 2 Ovarian cancer 2 Breast cancer metastatic 2 Ovarian epithelial cancer 1 Colorectal cancer metastatic 1 Ovarian cancer recurrent 1 Breast cancer recurrent 1 HER2 negative breast cancer 1 Neuroblastoma 1 Small cell lung cancer 1

Sponsors using this IMP

F. Hoffmann-La Roche AG 6 AstraZeneca AB 5 Pfizer Inc. 4 Alliance Foundation Trials LLC 2 ABCSG GmbH 1 BOOG Study Center B.V. 1 Celcuity Inc. 1 Champalimaud Clinical Centre 1 Consorzio Oncotech 1 Eli Lilly & Co. 1 ETOP IBCSG Partners Foundation 1 European Organisation For Research And Treatment Of Cancer 1

All trials — page 2

39 total

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Palbociclib and Fulvestrant versus Placebo Plus Palbociclib and Fulvestrant in… Ended

2023-505812-39-00 Phase III 9 countries F. Hoffmann-La Roche AG
Palbociclib for HR positive Isolated Local or Regional Recurrence of Breast Cancer Ended

2024-510776-20-00 Phase III 5 countries ETOP IBCSG Partners Foundation
A Phase II study of post-operative palbociclib as an alternative to chemotherapy in older patients with localized breast cancer at high risk… Ended

2023-505223-31-00 Phase II 7 countries European Organisation For Research And Treatment Of Cancer
Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended

2024-516204-42-00 Phase III 1 country BOOG Study Center B.V.
PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection Ended

2024-510704-37-00 Phase III 1 country Unicancer
PALLAS - PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy vers… Ended

2024-514841-12-00 Phase III 11 countries ABCSG GmbH; Alliance Foundation Trials LLC
PREDIX Luminal B - Neoadjuvant response-guided treatment of estrogen receptor positive tumors with high proliferation or slow proliferation … Ended

2024-519019-32-00 Phase II 1 country Karolinska University Hospital
PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCL… Ended

2024-511975-14-00 Phase I/II 5 countries Pfizer Inc.
Advanced hormone receptor-positive/HER2-negative/HER2-Enriched breast cancer Ended

2023-508828-35-01 Phase III 2 countries Solti Group
A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Ended

2024-519070-39-00 Phase II 1 country Region Hovedstaden
Study to evaluate the safety and tolerability of ZW25 in combination with palbociclib plus fulvestrant Ended

2023-508135-30-00 Phase II 1 country Jazz Pharmaceuticals Ireland Limited
MULTISARC : MOLECULAR PROFILING OF ADVANCED SOFT-TISSUE SARCOMAS. A phase III study Ended

2024-514873-22-00 Phase III 1 country Institut National De La Sante Et De La Recherche Medicale
Phase 1 / 2 study of amcenestrant (SAR439859) single agent and in combination with other anti-cancer therapies in postmenopausal women with … Ended

2024-512997-89-00 Phase I (FiH) 2 countries Sanofi-Aventis Recherche & Developpement
Clinical trial to compare the efficacy and tolerability of fulvestrant (FaslodexTM) 500mg with placebo versus fulvestrant (FaslodexTM) 500mg… Ended

2024-516132-10-00 Phase II 2 countries Fundacion Grupo Espanol De Investigacion En Cancer De Mama
Phase 1/2 Study of Belzutifan Plus Palbociclib Versus Belzutifan in Advanced Renal Cell Carcinoma (RCC) Ended

2023-504963-17-00 Phase I/II 6 countries Merck Sharp & Dohme LLC

Showing 25–39 of 39 trials

← All drugs A–Z